Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Opdivo

Oct 08, 2024

OPDIVO Approved for Resectable NSCLC; Palvella Gets $2.6M FDA Grant; First Patient Dosed in UGN-103 Bladder Cancer Trial; Recordati Acquires ENJAYMO for $825 Million; AIRSUPRA Reduces Severe Asthma Exacerbations

Sep 23, 2024

Roche’s TECENTRIQ HYBREZA: Setting New Standards as the First Subcutaneous Anti-PD-(L)1 Drug

Jun 14, 2024

OPDIVO vs. KEYTRUDA: The Battle for Japan’s PD-1 Inhibitor Market Dominance

May 31, 2024

The Journey of PD-(L)1 Inhibitors: Milestones and Breakthroughs

Jan 10, 2022

Novel and Emerging Metastatic Colorectal Cancer Treatment Drugs Anticipated to Change Market Dynamics

Jun 05, 2020

Prostate Cancer Market Experiences an Influx of the Pharma Players Veering the Market Ahead

May 01, 2020

Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses

Apr 21, 2020

COVID19 pipeline advances as Novartis begins phase III trial of hydroxychloroquine; and advancements in RCC, and HER2 positive breast cancer market

Feb 20, 2020

Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust

Jan 15, 2020

Malignant Pleural Mesothelioma Upcoming Therapies

Newsletter/Whitepaper